Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Research & Development (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Research & Development for 7 consecutive years, with -$2.7 million as the latest value for Q4 2019.

  • For the quarter ending Q4 2019, Research & Development fell 123.33% year-over-year to -$2.7 million, compared with a TTM value of $18.1 million through Dec 2019, down 62.19%, and an annual FY2024 reading of $73.3 million, up 164.83% over the prior year.
  • Research & Development was -$2.7 million for Q4 2019 at Larimar Therapeutics, down from $8.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $17.7 million in Q4 2015 and bottomed at -$2.7 million in Q4 2019.
  • Average Research & Development over 5 years is $10.1 million, with a median of $10.4 million recorded in 2015.
  • The sharpest move saw Research & Development skyrocketed 211.91% in 2015, then plummeted 123.33% in 2019.
  • Year by year, Research & Development stood at $17.7 million in 2015, then tumbled by 58.91% to $7.3 million in 2016, then soared by 49.98% to $10.9 million in 2017, then increased by 5.0% to $11.5 million in 2018, then tumbled by 123.33% to -$2.7 million in 2019.
  • Business Quant data shows Research & Development for LRMR at -$2.7 million in Q4 2019, $8.0 million in Q3 2019, and $3.1 million in Q2 2019.